• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

4-1BB 信号增强了嵌合抗原受体修饰的 CD28 整合第二代 T 细胞的抗肿瘤活性。

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2 Generation Chimeric Antigen Receptor-Modified T Cells.

机构信息

Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.

Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, China.

出版信息

Front Immunol. 2020 Nov 13;11:539654. doi: 10.3389/fimmu.2020.539654. eCollection 2020.

DOI:10.3389/fimmu.2020.539654
PMID:33281809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7691374/
Abstract

While chimeric antigen receptor-modified T (CAR-T) cells have shown great success for the treatment of B cell leukemia, their efficacy appears to be compromised in B cell derived lymphoma and solid tumors. Optimization of the CAR design to improve persistence and cytotoxicity is a focus of the current CAR-T study. Herein, we established a novel CAR structure by adding a full length 4-1BB co-stimulatory receptor to a 28Z-based second generation CAR that targets CD20. Our data indicated that this new 2028Z-4-1BB CAR-T cell showed improved proliferation and cytotoxic ability. To further understand the mechanism of action, we found that constitutive 4-1BB sensing significantly reduced the apoptosis of CAR-T cells, enhanced proliferation, and increased NF-κB pathway activation. Consistent with the enhanced proliferation and cytotoxicity , this new structure of CAR-T cells exhibited robust persistence and anti-tumor activity in a mouse xenograft lymphoma model. This work provides evidence for a new strategy to optimize the function of CAR-T against lymphoma.

摘要

嵌合抗原受体修饰的 T（CAR-T）细胞在治疗 B 细胞白血病方面取得了巨大成功，但在 B 细胞来源的淋巴瘤和实体瘤中的疗效似乎受到了影响。优化 CAR 设计以提高持久性和细胞毒性是当前 CAR-T 研究的重点。在此，我们通过在靶向 CD20 的基于 28Z 的第二代 CAR 上添加全长 4-1BB 共刺激受体，建立了一种新型的 CAR 结构。我们的数据表明，这种新型的 2028Z-4-1BB CAR-T 细胞显示出改善的增殖和细胞毒性能力。为了进一步了解作用机制，我们发现组成型 4-1BB 感应显著降低了 CAR-T 细胞的凋亡，增强了增殖，并增加了 NF-κB 通路的激活。与增强的增殖和细胞毒性一致，这种新型 CAR-T 细胞在小鼠异种移植淋巴瘤模型中表现出强大的持久性和抗肿瘤活性。这项工作为优化 CAR-T 对抗淋巴瘤的功能提供了新的策略证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/a3fb3303c1b5/fimmu-11-539654-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/3666d3fb789b/fimmu-11-539654-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/1680f7c97fbb/fimmu-11-539654-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/77183c53aea8/fimmu-11-539654-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/0dd5474622e4/fimmu-11-539654-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/869b0d740f94/fimmu-11-539654-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/a3fb3303c1b5/fimmu-11-539654-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/3666d3fb789b/fimmu-11-539654-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/1680f7c97fbb/fimmu-11-539654-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/77183c53aea8/fimmu-11-539654-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/0dd5474622e4/fimmu-11-539654-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/869b0d740f94/fimmu-11-539654-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0166/7691374/a3fb3303c1b5/fimmu-11-539654-g006.jpg

相似文献

1
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2 Generation Chimeric Antigen Receptor-Modified T Cells.4-1BB 信号增强了嵌合抗原受体修饰的 CD28 整合第二代 T 细胞的抗肿瘤活性。
Front Immunol. 2020 Nov 13;11:539654. doi: 10.3389/fimmu.2020.539654. eCollection 2020.
2
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.临床前优化 CD20 特异性嵌合抗原受体载体和培养条件。
J Immunother. 2018 Jan;41(1):19-31. doi: 10.1097/CJI.0000000000000199.
3
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.4-1BB 共刺激和优化的 CD28 共刺激增强了人单特异性和双特异性第三代 CAR T 细胞的功能。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003354.
4
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.嵌合抗原受体 T 细胞共转导 CD28 和 4-1BB 基因在 B 细胞白血病患者体内的扩增与抗肿瘤活性。
Mol Ther. 2018 Apr 4;26(4):976-985. doi: 10.1016/j.ymthe.2018.01.022. Epub 2018 Feb 2.
5
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.嵌合抗原受体双信号结构域（CD28 和 4-1BB 结构域）修饰的靶向 CD20 的细胞免疫治疗淋巴瘤的临床研究
Blood. 2012 Apr 26;119(17):3940-50. doi: 10.1182/blood-2011-10-387969. Epub 2012 Feb 3.
6
Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.使用第二代包含 CD28 或 4-1BB 的 CD19 CAR-T 治疗急性淋巴细胞白血病。
Br J Haematol. 2018 May;181(3):360-371. doi: 10.1111/bjh.15195. Epub 2018 Apr 10.
7
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain.嵌合抗原受体修饰 T 细胞的区域性递送可有效靶向 HER2 阳性乳腺癌脑转移。
Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23.
8
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
9
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.联合CD28和4-1BB共刺激增强亲和力优化的嵌合抗原受体工程化T细胞。
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
10
Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.利用4-1BB ζ嵌合抗原受体将T细胞重定向至磷脂酰肌醇蛋白聚糖-3可导致Th1极化和强大的抗肿瘤活性。
Hum Gene Ther. 2017 May;28(5):437-448. doi: 10.1089/hum.2016.025. Epub 2016 Aug 16.

引用本文的文献

1
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
2
Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review.释放嵌合抗原受体巨噬细胞（CAR-M）疗法在实体瘤中的潜力：一项全面综述。
Front Immunol. 2025 Jun 12;16:1615760. doi: 10.3389/fimmu.2025.1615760. eCollection 2025.
3
From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy.

本文引用的文献

1
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.THEMIS-SHP1 通过 4-1BB 招募调控嵌合抗原受体重定向 T 细胞的 LCK 介导的启动。
Cancer Cell. 2020 Feb 10;37(2):216-225.e6. doi: 10.1016/j.ccell.2019.12.014. Epub 2020 Jan 30.
2
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.CD19 CAR T 细胞疗法治疗急性淋巴细胞白血病后复发的机制及其预防和治疗策略。
Front Immunol. 2019 Nov 12;10:2664. doi: 10.3389/fimmu.2019.02664. eCollection 2019.
3
Production and Application of Multicistronic Constructs for Various Human Disease Therapies.
从分子设计到临床转化：癌症免疫治疗中的双靶点嵌合抗原受体T细胞策略
Int J Biol Sci. 2025 Mar 31;21(6):2676-2691. doi: 10.7150/ijbs.108036. eCollection 2025.
4
CAR-T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View.用于血液系统肿瘤和实体瘤的CAR-T细胞制造：从临床前到临床的视角
Cancer Med. 2025 Mar;14(5):e70726. doi: 10.1002/cam4.70726.
5
Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study.新型B7-H3嵌合抗原受体T细胞在胶质母细胞瘤中显示出强大的抗肿瘤作用：一项临床前研究。
J Immunother Cancer. 2025 Jan 25;13(1):e010083. doi: 10.1136/jitc-2024-010083.
6
[The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].[B 细胞急性淋巴细胞白血病中 CD19 CAR-T 细胞治疗后阳性复发的机制及挽救治疗策略]
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):970-976. doi: 10.3760/cma.j.cn121090-20240701-00242.
7
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.BCMA 嵌合抗原受体 T 细胞治疗后复发的多发性骨髓瘤患者的机制和挽救治疗。
Front Immunol. 2024 Oct 22;15:1433774. doi: 10.3389/fimmu.2024.1433774. eCollection 2024.
8
Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR-T-Cell Therapy.解锁凋亡途径：克服 CAR-T 细胞疗法中的肿瘤耐药性。
Cancer Med. 2024 Oct;13(19):e70283. doi: 10.1002/cam4.70283.
9
A CAR enhancer increases the activity and persistence of CAR T cells.一种嵌合抗原受体（CAR）增强子可提高CAR T细胞的活性和持久性。
Nat Biotechnol. 2024 Jul 30. doi: 10.1038/s41587-024-02339-4.
10
CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma.同时靶向 FGFR4 和 CD276 的 CAR T 细胞对儿童横纹肌肉瘤显示出强大的抗肿瘤作用。
Nat Commun. 2024 Jul 23;15(1):6222. doi: 10.1038/s41467-024-50251-x.
用于多种人类疾病治疗的多顺反子构建体的生产与应用。
Pharmaceutics. 2019 Nov 6;11(11):580. doi: 10.3390/pharmaceutics11110580.
4
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.低亲和力 CD19 CAR 治疗儿童 ALL 患者可增强 CAR T 细胞扩增和延长持久性。
Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2.
5
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.分泌双特异性 T 细胞衔接子（BiTEs）的 CAR-T 细胞可规避抗原逃逸而无明显毒性。
Nat Biotechnol. 2019 Sep;37(9):1049-1058. doi: 10.1038/s41587-019-0192-1. Epub 2019 Jul 22.
6
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.通过平衡激动强度与 FcγR 亲和力优化 4-1BB 抗体用于癌症免疫治疗。
Nat Commun. 2019 May 20;10(1):2141. doi: 10.1038/s41467-019-10088-1.
7
A safe and potent anti-CD19 CAR T cell therapy.一种安全有效的抗 CD19 CAR T 细胞疗法。
Nat Med. 2019 Jun;25(6):947-953. doi: 10.1038/s41591-019-0421-7. Epub 2019 Apr 22.
8
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.联合CD28和4-1BB共刺激增强亲和力优化的嵌合抗原受体工程化T细胞。
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
9
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.CD40 配体修饰的嵌合抗原受体 T 细胞通过引发内源性抗肿瘤反应增强抗肿瘤功能。
Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.
10
Controversies in the Treatment of Classical Hodgkin Lymphoma.经典型霍奇金淋巴瘤治疗中的争议
Hemasphere. 2018 Oct;2(5):e149. doi: 10.1097/HS9.0000000000000149. Epub 2018 Oct 2.